BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Suda G, Ogawa K, Morikawa K, Sakamoto N. Treatment of hepatitis C in special populations. J Gastroenterol 2018;53:591-605. [PMID: 29299684 DOI: 10.1007/s00535-017-1427-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Erken E, Altunoren O, Gungor O. Poor management of hepatitis C infection will cause serious issues for patients with advanced chronic kidney disease. J Evid Based Med 2021;14:87-9. [PMID: 33988914 DOI: 10.1111/jebm.12433] [Reference Citation Analysis]
2 Wolf HM, Eibl MM, Müller CJ. Oral direct-acting antiviral therapy for hepatitis C virus infection in X-linked agammaglobulinemia. J Allergy Clin Immunol Pract 2019;7:1049-51. [PMID: 30339854 DOI: 10.1016/j.jaip.2018.10.010] [Reference Citation Analysis]
3 Huang MH, Li H, Xue R, Li J, Wang L, Cheng J, Wu Z, Li W, Chen J, Lv X, Li Q, Lan P, Zhao L, Yang Y, Peng Z, Jiang J. Up-regulation of glycolipid transfer protein by bicyclol causes spontaneous restriction of hepatitis C virus replication. Acta Pharm Sin B 2019;9:769-81. [PMID: 31384537 DOI: 10.1016/j.apsb.2019.01.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
4 Tokuchi Y, Suda G, Kimura M, Maehara O, Kitagataya T, Kubo A, Yoshida S, Fu Q, Yang Z, Hosoda S, Ohara M, Yamada R, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Ohnishi S, Sakamoto N. Possible correlation between increased serum free carnitine levels and increased skeletal muscle mass following HCV eradication by direct acting antivirals. Sci Rep 2021;11:16616. [PMID: 34400736 DOI: 10.1038/s41598-021-96203-z] [Reference Citation Analysis]
5 Dong Y, Zhi X, Lei G. Changes of body immunity and inflammatory response in HIV/HCV co-infected patients. Exp Ther Med 2019;17:403-7. [PMID: 30651812 DOI: 10.3892/etm.2018.6938] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Hoppmann N, Massoud O. Medical care of liver transplant patients. Expert Rev Gastroenterol Hepatol 2020;14:901-18. [PMID: 32684007 DOI: 10.1080/17474124.2020.1797483] [Reference Citation Analysis]
7 Tokuchi Y, Suda G, Kimura M, Maehara O, Kitagataya T, Ohara M, Yamada R, Shigesawa T, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N. Changes in the estimated renal function after hepatitis C virus eradication with direct-acting antiviral agents: Impact of changes in skeletal muscle mass. J Viral Hepat 2021;28:755-63. [PMID: 33587828 DOI: 10.1111/jvh.13484] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Kawagishi N, Suda G, Kimura M, Maehara O, Shimazaki T, Yamada R, Kitagataya T, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Umemura M, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Kudo Y, Nishida M, Sakamoto N. High serum angiopoietin‐2 level predicts non‐regression of liver stiffness measurement‐based liver fibrosis stage after direct‐acting antiviral therapy for hepatitis C. Hepatol Res 2020;50:671-81. [DOI: 10.1111/hepr.13490] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
9 Nicastro E, Norsa L, Di Giorgio A, Indolfi G, D'Antiga L. Breakthroughs and challenges in the management of pediatric viral hepatitis. World J Gastroenterol 2021; 27(20): 2474-2494 [PMID: 34092970 DOI: 10.3748/wjg.v27.i20.2474] [Reference Citation Analysis]
10 Suda G, Hasebe C, Abe M, Kurosaki M, Itakura J, Izumi N, Uchida Y, Mochida S, Haga H, Ueno Y, Abe K, Takahashi A, Ohira H, Tsukuda Y, Furuya K, Baba M, Yamamoto Y, Kobayashi T, Inoue J, Terasita K, Ohara M, Kawagishi N, Izumi T, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group. Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection. J Gastroenterol 2019;54:641-9. [PMID: 30778716 DOI: 10.1007/s00535-019-01556-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
11 Suda G, Nakai M, Sho T, Kimura M, Shimazaki T, Maehara O, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Umemura M, Kawagishi N, Baba M, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group. The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment. Intern Med 2019;58:943-7. [PMID: 30568153 DOI: 10.2169/internalmedicine.2077-18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
12 Sho T, Suda G, Kimura M, Shimazaki T, Maehara O, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Umemura M, Izumi T, Kawagishi N, Baba M, Nakai M, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group. Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three Cases. Intern Med 2019;58:797-802. [PMID: 30449808 DOI: 10.2169/internalmedicine.1856-18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Kawagishi N, Suda G, Kimura M, Maehara O, Yamada R, Tokuchi Y, Kubo A, Kitagataya T, Shigesawa T, Suzuki K, Ohara M, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Kudo Y, Nishida M, Sakamoto N. Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C. Sci Rep 2021;11:9207. [PMID: 33911145 DOI: 10.1038/s41598-021-88632-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Aguilar C, Husain S, Lortholary O. Recent advances in understanding and managing infectious diseases in solid organ transplant recipients. F1000Res 2018;7:F1000 Faculty Rev-661. [PMID: 29899970 DOI: 10.12688/f1000research.14262.1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
15 Suda G, Sakamoto N. Recent advances in the treatment of hepatitis C virus infection for special populations and remaining problems. J Gastroenterol Hepatol 2021;36:1152-8. [PMID: 32667068 DOI: 10.1111/jgh.15189] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Isoda H, Oeda S, Takamori A, Sato K, Okada M, Iwane S, Takahashi H, Anzai K, Eguchi Y, Fujimoto K. Generation Gap for Screening and Treatment of Hepatitis C Virus in Saga Prefecture, Japan: An Administrative Database Study of 35,625 Subjects. Intern Med 2020;59:169-74. [PMID: 31534084 DOI: 10.2169/internalmedicine.3248-19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]